Two questions travel together in search results and they have almost nothing to do with each other. One is whether these drugs blunt the urge to drink, which now has randomized trials behind it. The other is whether it is safe to have a glass of wine on a Saturday while taking one, which the labeling addresses by not addressing it. Keeping them apart is the only way either answer stays honest.
Where the craving reports came from
The signal did not start with patients posting about losing interest in beer. Alcohol intake fell in rodents and in nonhuman primates given GLP-1 receptor agonists, and that animal work is the reason the first human trial was run at all.[2] Anecdote arrived later and found a hypothesis already waiting for it.
That sequence matters, because it means the question was designed rather than reverse-engineered from testimonials. It also means the trials were built to measure drinking, not weight, so their results do not automatically transfer to the people reading a price board for weight loss.
The randomized record, trial by trial
The first was exenatide. Researchers randomized 127 treatment-seeking patients with alcohol use disorder to 2 mg weekly or placebo for 26 weeks, on top of standard cognitive-behavioral therapy. On the primary endpoint, heavy drinking days, the drug did not beat placebo. Imaging told a different story: alcohol cue reactivity was attenuated in the ventral striatum and septal area, and dopamine transporter availability was lower in the treated group. An exploratory subgroup with a body mass index above 30 did show reduced heavy drinking days and lower total intake.[2]
The second was a phase 2 semaglutide trial in 48 non-treatment-seeking adults with alcohol use disorder, run over nine weeks at low doses. In a laboratory self-administration task, participants on semaglutide drank less, with effect estimates of −0.48 (95% CI −0.85 to −0.11) for grams of alcohol consumed and −0.46 (−0.87 to −0.06) for peak breath alcohol concentration. Weekly craving fell. Notably, average drinks per calendar day and the number of drinking days did not move; what fell was drinks per drinking day.[1]
The third and largest is a 26-week trial of semaglutide 2.4 mg in 108 treatment-seeking participants who had both moderate to severe alcohol use disorder and obesity. Heavy drinking days fell 41.1 percentage points from baseline on semaglutide against 26.4 points on placebo, an estimated treatment difference of −13.7 points (95% CI −22.0 to −5.4).[3]
Read the placebo column before the drug column. Two-thirds of the improvement happened in people who received saline and therapy. The drug added a real increment on top of that, and the increment is the claim.
What the population data can and cannot settle
A Swedish national cohort followed 227,866 people with alcohol use disorder from 2006 to 2023 and compared each person against themselves during periods on and off treatment. Semaglutide use, in 4,321 people, was associated with an adjusted hazard ratio of 0.64 (95% CI 0.50 to 0.83) for hospitalization due to alcohol use disorder. Liraglutide came in at 0.72. Approved medications for the condition managed 0.98.[4]
The within-individual design removes every fixed difference between people, which is its strength. It cannot remove the reason a particular person started the drug in a particular month, and starting a weight treatment often coincides with other changes.
A 2025 systematic review pooled fourteen studies covering more than five million people and reported a mean reduction of 7.81 points (95% CI 9.02 to 6.60) on the AUDIT screening scale, which runs from 0 to 40.[5] That pooled figure mixes four randomized trials with ten observational datasets on a self-reported instrument, so it reads as far more precise than the randomized evidence underneath it.
Drinking while taking one is a different question
The current prescribing information for the branded semaglutide and tirzepatide weight products contains no alcohol warning, no alcohol contraindication and no drug interaction entry for alcohol. The word appears in those documents only as the swab in the injection instructions and, in the tirzepatide multi-dose presentations, as benzyl alcohol among the inactive ingredients. That is the whole census.
Silence is not endorsement, and three labeled facts are worth carrying into the decision anyway. Both products warn that combining them with insulin or with certain other diabetes medicines raises the risk of low blood sugar. Both instruct stopping the drug if pancreatitis is suspected, and heavy drinking is itself a common cause of acute pancreatitis, so severe abdominal pain after a heavy night is not a symptom to sleep off. Both carry a warning about kidney injury from dehydration when vomiting is repeated, which is a bad combination with a substance that also dehydrates.
Reports of lower tolerance circulate widely. No trial above measured alcohol absorption or intoxication, and neither label records anything on the point, so there is no number to give. Nausea, by contrast, is well described, and its timing is predictable enough to plan around. The broader tolerability picture sits in the side-effect data.
What none of this authorizes
No GLP-1 drug is approved for alcohol use disorder in the United States. The approved indications for the branded semaglutide product are cardiovascular risk reduction, weight reduction and a liver condition. Prescribing for drinking is off-label, and the trials above enrolled people with a diagnosis, under supervision, alongside therapy.
That gap matters commercially. A telehealth intake built to assess weight eligibility is not built to assess a substance use disorder, and a seller advertising the craving effect is advertising past the evidence and past its own scope of practice. What each intake actually asks is part of what a provider review records, against the criteria in the methodology. Most of what is sold here is compounded product, which arrives without the labeling quoted above.
None of this is medical advice. Anyone weighing a drink against a prescription has a conversation to have with a prescriber, and anyone who suspects their drinking is a problem has a different and more important one.